The role of death receptor ligands in shaping tumor microenvironment

Immunological Investigations

Volumn 36, Issue 1, 2007, Pages 25-46

  Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; FasL; Inflammation; TRAIL; Tumor escape

Indexed keywords

CASPASE 8; CHEMOKINE; CYTOKINE; DEATH RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FAS LIGAND ANTIBODY; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CROSS LINKING; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; INFLAMMATION; NATURAL KILLER T CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; FAS LIGAND PROTEIN; IMMUNITY, CELLULAR; INFLAMMATION; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR ESCAPE;

EID: 33845945485     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130600991893     Document Type: Article

References (103)

1. Aggarwal, B. B. (2004). Nuclear factor-κB: the enemy within. Cancer Cell 6:203-208.
2. Aller, M. A., Arias, J. L., Nava, M. P., Arias, J. (2004). Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine function systems. Exp. Biol. Med. 229:170-181.
3. Allison, J., Georgiou, H. M., Strausser, A., Vaux, D. L. (1997). Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. PNAS USA 94:3943-3947.
4. Almasan, A., Ashkenazi, A. (2003). Apo2L/TRAIL: apoptosis, signaling, biology and potential for cancer therapy. Cytokine Growth Factor Rev. 14:337-348.
5. Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Squarcina, P., Accornero, P., Lozupone, F., Lugini, L., Stringaro, A., Molinari, A., Arancia, G., Gentile, M., Parmiani, G., Fais, S. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of FasF - bearing microvesicles. J. Exp. Med. 195:1303-1316.
6. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., Schwall, R. H. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:155-162.
7. Askenazy, N., Yolcu, E. S., Yaniv, I., Shirwan, H. (2005). Induction of tolerance using FasL: a double-edged immunomodulator. Blood 105:1396-1404.
8. Balkwill, F., Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357:539-545.
9. Balkwill, F., Coussens, L. M. (2004a). Cancer: An inflammatory link. Nature 431: 405-406.
10. Balkwill, F. (2004b). Cancer and the chemokine network. Nat. Rev. Cancer 4:540-550.
11. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., Shanahan F. (1998). The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-5675.
12. Bodmer, J. L., Holler, N., Reynards, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., Tschopp, J. (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241-243.
13. Bosque, A., Pardo, J., Martinez-Lorenzo, M. J., Iturralde, M., Marzo, I., Pineiro, A., Alava, M. A., Naval, J., Anel, A. (2005a). Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c-FLIP, Bim, or Bcl-x isoform expression. J Leuk Biol 77:568-578.
14. Bosque, A., Pardo, J., Martinez-Lorenzo, M. J., Lasierra, P., Larrad, L., Marzo, I., Naval, J., Anel, A. (2005b). Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur. J. Immunol. 35:1812-1821.
15. Bron, L. P., Scolyer, R. A., Thompson, J. F., Hersey, P. (2004). Histological expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 36:561-565.
16. Bullani, R. R., Huard, B., Viard-Leveugle, I., Byers, H. R., Irmler, M., Saurat, J. H., Tschopp, J., French, L. E. (2001). Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 117:360-364.
17. Chen, Y. L., Chen, S. H., Wang, J. Y., Yang, B. C. (2003). Fas ligand on tumor cells mediates inactivation of neutrophils. J. Immunol. 171:1183-1191.
18. Davidson, W. F., Giese, T., Fredrickson, T. N. (1998). Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187:1825-1838.
19. Denko, N. C., Fontana, L. A., Hudson, K. M., Sutphin, P. D., Raychaudhuri, S., Altman, R., Giaccia, A. J. (2003). Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914.
20. Dutton, A., Young, L. S., Murray, P. G. (2006). The role of cellular flice inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Exp. Opin. Ther. Targets 10:27-35.
21. Farrow, B., Sugiyama, Y., Chen, A., Uffort, E., Nealon, W., Mark Evers, B. (2004). Inflammatory mechanisms contributing to pancreatic cancer development. Ann. Surg. 239:763-769.
22. Ferguson, T. A., Green, D. R. (2001). Fas ligand and immune privilege: the eyes have it. Cell Death Differ. 8:771-772.
23. Franco, A. V., Zhang, X. D., Van Berkel, E., Sanders, J. E., Zhang, X. Y., Thomas, W. D., Nguyen, T., Hersey, P. (2001). The role of NF-êB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J. Immunol. 166:5337-5345.
24. French, L. E., Tschopp, J. (2003). Protein-based therapeutic approaches targeting death receptors. Cell Death Diff. 10:117-123.
25. Gastman, B. R., Atarashi, Y., Reichert, T. E., Saito, T., Balkir, L., Rabinowich, H., Whiteside, T. L. (1999). Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res. 59:5356-5364.
26. Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z. W., Egan, L. J., Kagnoff, M. F., Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296.
27. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., Ferguson, T. A. (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192.
28. Haefner, B. (2005). The transcription factor NF-êB as drug target. Prog. Med. Chem. 43:137-188.
29. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., Tschopp, J. (1996). Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366.
30. Hanada, T., Yoshimura, A. (2002). Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13:413-421.
31. Helbig, G., Christopherson, K. W. 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., Nakshatri, H. (2003). NF-κ B promotes breast cancer migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278:21631-21638.
32. Hersey, P., Zhang, X. D. (2003). Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol. 196:9-18.
33. Hildeman, D. A., Zhu, Y., Mitchell, T. (2002). Molecular mechanisms of activated T-cell death in vivo. Curr. Opin. Immunol. 14:354-359.
34. Hohlbaum, A. M., Gregory, M. S., Ju, S. T., Marshak-Rothstein, A. (2001). Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167:6217-6224.
35. Huber, M. A., Azoitei, N., Baumann, B., Grunert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., Wirth, T. (2004). NF-κ B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 114:569-581.
36. Ito, Y., Monden, M., Takeda, T., Eguchi, H., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., Sakon, M., Nakamura, M., Tsujimoto, M., Nakahara, M., Nakao, K., Yokosaki, Y., Matsuura, N. (2000). The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br. J. Cancer. 82:1211-1217.
37. Jo, M., Kim, T. H., Seol, D. W., Esplen, J. E., Dorko, K., Billiar, T. R., Strom, S. C. (2000). Apoptosis induced in normal hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6:564-567.
38. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H., Golstein, P. (1994). Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530.
39. Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., Baekkeskov, S. (1997). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-743.
40. Kashii, Y., Giorda, R., Herberman, R. B., Whiteside, T. L., Vujanovic, N. L. (1999). Constitutive expression and role of the tumor necrosis factor family ligands in apoptotic killing of tumor cells by human natural killer cells. J. Immunol. 163:5358-5366.
41. Kim, J.-W., Wieckowski, E., Taylor, D. D., Reichert, T. E., Watkins, S., Whiteside, T. L. (2005). FasL+ membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 11:1010-1020.
42. Kreuz, S., Siegmund, D., Rumpf, J.-J., Samel, D., Leverkus, M., Janssen, O., Hacker, G., Dittrich-Breiholz, O., Kracht, M., Scheurich, P., Wayant, H. (2004). NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 166:369-380.
43. Krueger, A., Baumann, S., Krammer, P. H., Kirchhoff, S. (2001). FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21, 8247-8254.
44. Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung, S., Khan, L., Gliniak, B., Bussiere, J., Smith, C. A., Strom, S. S., Kelley, S., Fox, J. A., Thomas, D., Ashkenazi, A. (2001). Differential hepatocyte toxicity of recombinant APO2L/TRAIL versions. Nat. Med. 7:383-385.
45. Li, X. K., Okuyama, T., Tamura, A., Enosawa, S., Kaneda, Y., Takahara, S., Funashima, N., Yamada, M., Ameniya, H., Suzuki, S. (1998). Prolonged survival of rat liver allografts transfected with FasLigand-expressing plasmid. Transplantation 66:1416-1423.
46. Locksley, R. M., Killeen, N., Lenardo, M. J. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501.
47. Lotze, M. T., DeMarco, R. A. (2004). Dying dangerously: necrotic cell death and chronic inflammation promote tumor growth. Discovery Med. 4:448-456.
48. Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H., Karin, M. (2004). Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. Cancer Cell 6:297-305.
49. Malik, S. T., Griffin, D. B., Fiers, W., Balkwill, F. R. (1989). Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int. J. Cancer 44:918-925.
50. Mann, B., Gratchev, A., Bohm, C., Hanski, M. L., Foss, H. D., Demel, G., Trojanek, B., Schmidt-Wolf, I., Stein, H., Riecken, E. O., Buhr, H. J., Hanski, C. (1999). FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 79:1262-1269.
51. Martinez-Lorenzo, M. J., Alva, M. A., Gamen, S., Kim, K. J., Chuntharapai, A., Pineiro, A., Naval, J., Anel, A. (1998). Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 28:2714-2725.
52. Martinez-Lorenzo, M. J., Anel, A., Alava, M. A., Pineiro, A., Naval, J., Lasierra, P., Larrad, L. (2003). The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contributions to tumor counterattack. Exp. Cell Res. 295:315-329.
53. McCawley, L. J., Martisian, L. M. (2001). Tumor progression: defining the soil round the tumor seed. Curr. Biol. 11:R25-R27.
54. Medema, J. P., de Jong, J., van Hall, T., Melief, C. J., Offringa, R. (1999). Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1033-1038.
55. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., Tschopp, J. (2001). NF-κB signals induce the expression of c-FLIP. Mol. Cell Biol. 21:5299-5305.
56. Micheau, O., Tschopp, J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
57. Miwa, K., Asano, M., Horai, R., Lwakura, Y, Nagata, S., Suda, T. (1998). Caspase 1-independent IL-1 beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 4:1287-1292.
58. Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., Kollias, G., Balkwill, F. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5:828-831.
59. Munakata, S., Enomoto, T., Tsujimoto, M., Otsuki, Y., Miwa, H., Kanno, H., Aozasa, K. (2000). Expression of Fas ligand and other apoptosis related genes and their prognostic significance in epithelial ovarian neoplasms. Br. J. Cancer 82:1446-1452.
60. Nagata, S., Suda, T. (1995). Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16:39-43.
61. Nozoe, T., Yasuda, M., Honda, M., Inutsuka, S., Korenaga, D. (2003). Fas ligand expression is corelated with metastasis in colorectal carcinoma. Oncology 65:83-88.
62. Okada, K., Komuta, K., Hashimoto, S., Matsuzaki, S., Kanematsu, T., Koji, T. (2000). Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res. 6:3560-3564.
63. O'Brien, D. I., Nally, K., Kelly, R. G., O'Connor, T. M., Shanahan, F., O'Connell, J. (2005). Targeting the Fas/Fas ligand pathway in cancer. Exp. Opin. Ther. Targets 9:1031-1044.
64. O'Connell, J., O'Sullivan, G. C., Collins, J. K., Shanahan, F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075-1082.
65. O'Connell, J., Bennett, M. W., O'Sullivan, G. C., Roche, D., Kelly, J., Collins, J. K., Shanahan, F. (1998). Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186:240-246.
66. Ottonello, L., Tortolina, G., Amelotti, M., Dallegri, F. (1999). Soluble FasL is chemotactic for human neutrophilic polymosphonuclear leukocytes. J. Immunol. 162:3601-3606.
67. Park, D. R., Thomsen, A. R., Frevert, C. W., Pham, U., Skerrett, S. J., Kiener, P. A., Liles, W. C. (2003). Fas (CD95) induces pro-inflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J. Immunol. 170:6209-6216.
68. Perkins, N. D. (2004). NF-κB: tumor promoter or suppressor? Trends Cell Biol. 14:64-69.
69. Peter, M. El, Krammer, P. H. (2003). The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
70. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., Ben-Neriah, Y. (2004). NF-κB functions as tumor promoter in inflammation-associated cancer. Nature 431:461-466.
71. Pitti, R. M., Marsters, S. A., Lawrence, D. A., Roy, M., Kischkel, F. C., Dowd, P., Huang, A., Donahue, C. J., Sherwood, S. W., Baldwin, D. T., Godowski, P. J., Wood, W. I., Gurney, A. L., Hillan, K. J., Cohen, R. L., Goddard, A. D., Botstein, D., Ashkenazi, A. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703.
72. Rabinowich, H., Reichert, T. E., Kashii, Y., Bell, M. C., Whiteside, T. L. (1998). Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J. Clin. Invest. 101:2579-2588.
73. Reichert, T. E., Strauss, L., Wagner, E. M., Gooding, W., Whiteside, T. L. (2002). Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 8:3137-3145.
74. Reimer, T., Herrnring, C., Koczan, P., Richter, D., Gerber, B., Kabelitz, D., Friese, K., Thiesen, H.-J. (2000). FasL:Fas ratio - a prognostic factor in breast carcinoma. Cancer Res. 60:822-828.
75. Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L., Kindler, V., Tschopp, J., Ricciardi-Castagnoli, P. (2000). Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1 beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192:1661-1668.
76. Schmaltz, C., Alpdogan, O., Kappel, B. J., Muriglan, S. J., Rotolo, J. A., Ongchin, J., Willis, L. M., Greenberg, A. S., Eng, J. M., Crawford, J. M., Murphy, G. F., Yagita, H., Walczak, H., Peschon, J. J., van den Brink, M. R. (2002). T cells require TRAIL for optimal graft-versus tumor activity. Nat. Med. 8:1433-1437.
77. Screpanti, V., Wallin, R. P. A., Grandien, A., Ljunggren, H.-G. (2004). Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol. Immunol. 42:495-499.
78. Sheehan, K. M., O'Donovan, D. G., Fitzmaurice, G., O'Grady, A., O'Donoghue, D. P., Sheahan, K., Byrne, M. F., Conroy, R. M., Kay, E. W., Murray, F. E. (2003). Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer. Eur J Gastroenterol Hepatol. 15:375-380.
79. Shishodia, S., Aggarwal, B. B. (2004). Nuclear factor-κB: a friend or foe in cancer? Biochem. Pharmacol. 68:1071-1080.
80. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y., Lenardo, M. J. (2000). Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288:2354-2357.
81. Siegmund, D., Wicovsky, A., Schmitz, I., Schulze-Osthoff, K., Kreuz, S., Leverkus, M., Dittrich-Breiholz, O., Kracht, M., Wajant, H. (2005). Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Mol. Cell. Biol. 25:6363-6379.
82. Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A., Thiel, M. (2004). Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22:657-682.
83. Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita, H., Okumura, K. (2001). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:661-670.
84. Smyth, M. J., Hayakawa, Y., Takeda, K., Yagita, H. (2002). New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2:850-861.
85. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., Galle, P. R. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366.
86. Strand, S., Vollmer, P., Van den Abeelen, L., Gottfried, D., Alla, V., Heid, H., Kuball, J., Theobald, M., Galle, P. R., Strand, D. (2004). Cleavage of CD95 by matrix metaboproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23:3732-3736.
87. Street, S. E., Cretney, E., Smyth, M. J. (2001). Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97:192-197.
88. Suganuma, M., Okabe, S., Marino, M. W., Sakai, A., Sueoka, E., Fujiki, H. (1999). Essential role of tumor necrosis factor alpha (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice. Cancer Res. 59:4516-4518.
89. Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Yamaguchi, N., Yagita, H., Okumura, K. (2001). Involvement of tumor necrosis-related apoptosis-inducing ligand in NK-cell mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 214:194-200.
90. Takeda, K., Smyth, M. J., Cretney, E., Hayakaw, A. Y., Kayagaki, N., Yagita, H., Okumura, K. (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195:161-169.
91. Talmadge, J. E., Meyers, K. M., Prieur, D. J., Starkey, J. R. (1980). Role of NK cells in tumour growth and metastasis in beige mice. Nature 284:622-624.
92. Van Parijs, L., Abbas, A. K. (1998). Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280:243-248.
93. Wajant, H. (2003). Death receptors. Essays Biochem. 39: 53-71.
94. Wajant, H. (2004). TRAIL and NF κB signaling - a complex relationship. Vitam. Horm. 67 101-132.
95. Wajant, H. (2006). CD95/FasL and TRAIL in tumour surveillance and cancer therapy. In: Dalgleish, A. G., Haefner, B. ed. The Link Between Inflammation and Cancer. Springer, New York, pp. 141-166.
96. Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C., Lynch, D. H. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
97. Wang, L., Walia, B., Evans, J., Gewirtz, A. T., Merlin, D. (2003). IL-6 induces NF-κB activation in the intestional epithelia. J. Immunol. 171:3194-3201.
98. Whiteside, T. L. (2002). Tumor-induced death of immune cells: its mechanisms and consequences. Sem. Cancer Biol. 12:43-50.
99. Whiteside, T. L. (2004). Down-regulation of ζ chain expression in T cells: A biomarker of prognosis in cancer? Cancer Immunol. Immunother. 53:865-876.
100. Whiteside, T. L. (2006). The role of immune cells in the tumor microenvironment. In: Dalgleish, A.G, Haefner, B. ed. The Link Between Inflammation and Cancer: Wounds That Do Not Heal. Springer: New York, pp. 103-124.
101. Yoong, K. F., Afford, S. C., Randhawa, S., Hubscher, S. G., Adams, P. H. (1999). Fas/FasL interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 154:693-703.
102. Younes, M., Schwartz, M. R., Ertan, A., Finnie, D., Younes, A. (2000). Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88:524-528.
103. Zeh, H. J., Lotze, M. T. (2005). Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28:1-9.